DRMA Stock Analysis: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$1.34
-0.04 (-2.90%)
▼
5d:
+14.53%
30d:
-1.47%
90d:
+11.67%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DRMA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DRMA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $1.34, which is considered extended relative to its 30-day fair value range of $1.19 to $1.32.
Technical Outlook: Technically, DRMA is in a downtrend. Immediate support is located at $1.18, while resistance sits at $1.40.
Market Sentiment: DRMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.00 (+198.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DRMA is in a downtrend. Immediate support is located at $1.18, while resistance sits at $1.40.
Market Sentiment: DRMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.00 (+198.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.19 -
$1.32
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 198.5% below Wall St target ($4.00)
Trading Range Analysis
30-Day Trading Range
$1.19 -
$1.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.18
Resistance Level
$1.40
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.88
Wall Street Target
$4.00
(+198.5%)
Share & Embed Analysis
Last updated: July 03, 2026 12:42 AM ET
Data refreshes hourly during market hours. Next update: 1:42 AM
Data refreshes hourly during market hours. Next update: 1:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Munera Maria E Bedoya-To…
BUY
1000 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$291 | 63 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 61 BUY |
